The Wegovy Pill Is Here: What It Costs, How It Compares, and Where to Get It

How the Pill Works (and Why the Dose Looks Different)

The Wegovy pill contains the same active ingredient as injectable Wegovy: semaglutide. It works through GLP-1 receptor activation, primarily by reducing appetite and slowing digestion so you feel satisfied with less food. The clinical effect is the same.

The dosing numbers look very different, though, and there's a straightforward reason for that. When you inject semaglutide, about 89% of the dose reaches your bloodstream. When you swallow a semaglutide pill, only about 1% gets absorbed. To compensate, the pill dose is much larger: 25 mg daily for the pill vs 2.4 mg weekly for the injection.

You start at 1.5 mg and gradually increase over several months. The available tablet strengths are 1.5 mg, 4 mg, 9 mg, and 25 mg (the maintenance dose). Your provider will guide the dose escalation based on how you respond and how you tolerate each step.

Where to Get the Wegovy Pill

The Wegovy pill is a prescription medication, which means the first step is a consultation with a licensed clinician who can evaluate whether it's appropriate for you. You can't access the cash-pay pricing or pick it up at a pharmacy without a valid prescription.

Most people are getting started through telehealth providers, where the entire process happens online: medical evaluation, prescription (if appropriate), and medication shipped to your door. Novo Nordisk named Ro, LifeMD, and Weight Watchers as official launch partners in January 2026. GoodRx is also matching Novo's cash-pay pricing. FuturHealth has also added the Wegovy pill alongside their existing medication options. More providers are expected to follow as availability expands.

The pill is also available at over 70,000 US retail pharmacies (including CVS and Costco) and through NovoCare Pharmacy, Novo Nordisk's home delivery service. In both cases, you'll need a prescription from a licensed provider first.

Many telehealth weight loss programs go beyond just the prescription. They include ongoing clinician check-ins, health coaching, and app-based tracking, which research shows produces better long-term outcomes than medication alone. If you're weighing your options, compare providers offering GLP-1 programs to see what fits.

Pill vs Injection: How They Compare

Both forms deliver the same medication. The difference comes down to the daily routine and what trade-offs matter most to you.

Advantages of the pill

No needles. A significant number of eligible patients cite needle aversion as a barrier to starting GLP-1 treatment. The pill eliminates that entirely. No injection-site reactions, no refrigeration required, no learning how to self-inject.

Familiar routine. Taking a pill in the morning is something most people have done before. For some, that feels simpler than a weekly injection, even if the pill is daily.

Travel and storage. The pill doesn't need refrigeration, which makes travel easier. Injectable Wegovy needs to be kept cold, and traveling with needles can add friction at airports and hotels.

Advantages of the injection

Once a week. You inject once every seven days and you're done. The pill requires daily commitment, first thing every morning, on an empty stomach, with specific water and timing rules. Miss those conditions and absorption drops.

Slightly stronger data. In separate clinical trials, the injection showed about 14.9% average weight loss (all patients) vs about 13.6% for the pill. These weren't head-to-head comparisons, so the numbers aren't directly comparable, but the injection data is modestly stronger.

Approved for teens. The Wegovy injection is FDA-approved for ages 12 and up. The pill is currently approved for adults only.

Side effects

Both forms share the same common side effects: nausea, diarrhea, vomiting, constipation, and stomach pain. These tend to be most noticeable during dose escalation and often improve over time. For a detailed breakdown of side effect data from clinical trials, see our GLP-1 side effects guide.

The injection can cause reactions at the injection site (redness, swelling). The pill may cause more upper-GI discomfort because it's in direct contact with the stomach lining. Neither form has shown safety concerns that the other doesn't share.

What the Wegovy Pill Costs

The list price for the Wegovy pill is $1,349.02 per month, which is the same as the injectable version. Very few people pay list price, though. Several programs bring the cost down significantly.

Cash-pay through NovoCare

Novo Nordisk set up direct cash-pay pricing that doesn't require insurance:

• Starter doses (1.5 mg and 4 mg): $149/month
• Maintenance doses (9 mg and 25 mg): $299/month

The $149 price for the 4 mg dose is an introductory rate through April 15, 2026, after which it moves to $199/month. The 1.5 mg starter remains at $149.

These are medication-only prices. You still need a prescription from a licensed clinician to access NovoCare pricing, and that consultation typically happens through your doctor or a telehealth provider. Many telehealth programs charge a separate membership or program fee that covers the medical evaluation, ongoing check-ins, and support. While that adds to the monthly cost, it also means you're getting clinical oversight rather than just a prescription. Compare providers and their program pricing.

With insurance

If your insurance plan covers Wegovy (either form), the manufacturer savings card can bring your copay down to as low as $25/month. Coverage varies by plan, and most require prior authorization. Check with your insurer directly to find out if the pill is on your formulary. If you are denied, see our guide to appealing insurance denials.

The pill's starter dose is the cheapest entry point for any FDA-approved GLP-1 weight loss medication right now. For a broader look at how semaglutide pricing works across different paths, see our GLP-1 program costs guide.

Rybelsus vs the Wegovy Pill: Not the Same Thing

This is a common point of confusion worth clearing up. Rybelsus® is an older oral semaglutide pill that's been available since 2019. But it's FDA-approved for Type 2 diabetes, not weight loss, and the maximum dose is only 14 mg.

The Wegovy pill goes up to 25 mg and was specifically developed and tested for weight management. Everything from the dosing to the clinical trial data to the FDA indication is distinct.

To make the branding cleaner, Novo Nordisk is rebranding Rybelsus as "Ozempic® tablets" (expected to launch under that name in Q2 2026). Going forward, the naming will be more intuitive:

• Ozempic (injection and tablets): Semaglutide for Type 2 diabetes
• Wegovy (injection and tablets): Semaglutide for weight management

If you see "oral semaglutide" referenced without specifying Wegovy or the weight loss indication, make sure you know which product is being discussed. They're different medications with different clinical evidence, even though both contain semaglutide.

What About Compounded Oral GLP-1 Medications?

Several telehealth providers currently offer compounded oral GLP-1 medications as an alternative to both brand-name pills and injectable compounded versions. These are not FDA-approved and have not gone through the clinical trials that Wegovy® has, but they provide a lower-cost oral option for patients who want to avoid injections.

Who Offers Compounded Oral Options

SkinnyRx offers compounded semaglutide and tirzepatide tablets at $249/month (flat rate across all doses). Eden offers compounded tablets and gummies alongside their injectable options. Sprout Health offers compounded tirzepatide tablets, though not semaglutide tablets. All three are licensed telehealth providers using compounding pharmacies.

For context on what happened when a larger company tried this: in February 2026, Hims & Hers launched a compounded oral semaglutide pill at $49/month and pulled it within four days after intervention from the FDA, Novo Nordisk, and the Department of Justice. The enforcement was largely about the scale and marketing claims, not necessarily the concept of compounded oral medications through legitimate pharmacies.

The Absorption Question

This is the part that matters most for oral specifically. Novo Nordisk's Wegovy pill uses a patented absorption enhancer (salcaprozate sodium, or SNAC) to get semaglutide through the stomach lining. Without that technology, oral semaglutide absorbs poorly. Compounded oral tablets use different formulations, and whether they deliver the medication as effectively is an open question without published clinical data comparing them.

Sublingual tablets (dissolved under the tongue) bypass the stomach absorption issue by entering the bloodstream through oral tissue. SkinnyRx offers this as one of their three medication forms. It's a different delivery mechanism than swallowing a pill, which may address some of the absorption concern.

When Compounded Oral Might Make Sense

The reasons someone would consider a compounded oral option are similar to compounded injectables: brand-name medication costs more than they can afford, insurance doesn't cover GLP-1s for their situation, or they want to start treatment while working through insurance approval. The oral-specific appeal is avoiding injections entirely while still paying less than the Wegovy pill's $149-$299/month through NovoCare.

If you're considering this route, the same due diligence applies as with any compounded medication. Our compounded GLP-1 safety guide covers how to evaluate whether a provider and their pharmacy partners are operating legitimately.

What's Coming Next

The weight loss medication landscape is evolving fast. A few developments worth watching:

Wegovy 7.2 mg injection. Novo Nordisk has filed for FDA approval of a higher-dose injection. In clinical trials, this dose showed approximately 20.7% average weight loss, meaningfully more than either the current injection (2.4 mg) or the pill (25 mg). If approved, it would give the injectable form a clear efficacy advantage over the pill.

Eli Lilly's orforglipron. Lilly has its own oral GLP-1 in development. It uses a different active ingredient (not semaglutide), and notably, it does not require the empty-stomach/fasting instructions that the Wegovy pill does. Analysts expect a possible FDA decision as early as late March 2026. If approved, it would give patients a second oral option with a potentially simpler daily routine.

Insurance coverage expansion. The BALANCE Model creates a new Medicare pathway for GLP-1 coverage starting July 2026, with $50/month beneficiary cost. Broader coverage could significantly change the cost equation for brand-name medications.

All of this is likely to shift fast. We'll update the pricing and availability sections as approvals land and programs change.

Should You Choose the Pill or the Injection?

There's no universally right answer. It depends on what matters most to you.

If needles are a dealbreaker or you travel frequently, the pill removes those barriers entirely. No refrigeration, no injection supplies. At $149/month for the starter dose, it's also the most affordable entry point for FDA-approved GLP-1 weight loss treatment.

On the other hand, people who prefer a set-it-and-forget-it weekly routine may find the injection easier to sustain. You don't have to manage empty-stomach timing every morning, and the efficacy data is modestly stronger. The upcoming 7.2 mg dose would widen that gap further.

Either way, you'll need a prescription from a licensed provider. For a comparison of which medications different providers offer (semaglutide, tirzepatide, brand-name, compounded), see our semaglutide vs tirzepatide comparison.

Featured Programs with Clinician Support

These programs include licensed clinician consultations and structured support. Compare what's included before deciding.

Sources

1. U.S. Food and Drug Administration. Wegovy (semaglutide) tablets prescribing information. Approved December 22, 2025.
2. Wharton S, Lingvay I, et al. Oral semaglutide 25 mg for the treatment of obesity (OASIS 4). N Engl J Med. 2025.
3. Novo Nordisk. Wegovy pill now broadly available across America. January 5, 2026.
4. NovoCare. Wegovy pricing and savings.
5. FDA. FDA concerns with unapproved GLP-1 drugs used for weight loss. Updated February 2026.

Last updated: March 3, 2026. Pricing, availability, and regulatory status change frequently. Verify current information with your provider or the manufacturer before making treatment decisions.